DiscoverCME in Minutes: Education in DermatologyNikhil I. Khushalani, MD - From Trial to Team: Optimizing Adjuvant Immunotherapy for High-Risk Cutaneous Squamous Cell Carcinoma
Nikhil I. Khushalani, MD - From Trial to Team: Optimizing Adjuvant Immunotherapy for High-Risk Cutaneous Squamous Cell Carcinoma

Nikhil I. Khushalani, MD - From Trial to Team: Optimizing Adjuvant Immunotherapy for High-Risk Cutaneous Squamous Cell Carcinoma

Update: 2025-09-22
Share

Description

Please visit answersincme.com/860/TSG to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cutaneous oncology discusses evidence-based insights that inform the practical integration of adjuvant immunotherapy regimens into cutaneous squamous cell carcinoma (CSCC) care, based on available clinical data. Upon completion of this activity, participants should be better able to: Review the rationale for immunotherapy in the adjuvant treatment of patients with high-risk resected cutaneous squamous cell carcinoma (CSCC); Summarize the latest clinical trial data evaluating adjuvant immunotherapy in high-risk CSCC; and Outline evidence-based, multidisciplinary strategies to optimize the care of patients with high-risk CSCC in the adjuvant setting.
Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Nikhil I. Khushalani, MD - From Trial to Team: Optimizing Adjuvant Immunotherapy for High-Risk Cutaneous Squamous Cell Carcinoma

Nikhil I. Khushalani, MD - From Trial to Team: Optimizing Adjuvant Immunotherapy for High-Risk Cutaneous Squamous Cell Carcinoma

Answers in CME